Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY: OGEN )

0.2586 -0.0264 (-9.26%)
Official Closing Price Updated: 8:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc. Common Stock

< Previous 1 2 3 Next >
Oragenics to Participate in the World Vaccine Congress Washington
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
From Oragenics, Inc.
Via Business Wire
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Regains Compliance with NYSE American
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
From Oragenics, Inc.
Via Business Wire
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Receives NYSE American Notice
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces New Chair
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate in the 2022 BioFlorida Annual Conference
From Oragenics, Inc.
Via Business Wire
Oragenics Issues Letter to Shareholders
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
From Oragenics, Inc
Via Business Wire
Oragenics Issues Letter to Shareholders
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate at the World Vaccine Congress Washington 2022
From Oragenics, Inc.
Via Business Wire
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
From Oragenics, Inc.
Via Business Wire
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
From Oragenics, Inc.
Via Business Wire
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners
From Oragenics, Inc.
Via Business Wire
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
From Oragenics, Inc.
Via Business Wire
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.
From Oragenics, Inc.
Via Business Wire
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Postponement of Annual Meeting of Shareholders
From Oragenics, Inc.
Via Business Wire
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
From Oragenics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.